ANDERA PARTNERS
Follow13F filer, CIK 1757283, PARIS, France
ANDERA PARTNERS reported $175,700,568 across 7 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-10-16.
Accepted , ingested 13F-HR 0001757283-26-000022
- Period
- 2026-09-30
- Reported value
- $176M
- Holdings
- 7
- Top 10 weight
- 100%
- New
- 0
- Sold out
- 1
Part of the filer group ANDERA PARTNERS
BioDiscovery 6 FPCIFrancois Xavier Mauron
- BioDiscovery 6 FPCI
- Francois Xavier Mauron
- Stephane Bergez
Largest buys vs the previous quarter
None.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| EVMNreduced | -1,294,628 | -$10.7M |
| ABVXexited | -78,125 | -$10.4M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0001757283-26-000022, largest first. % of portfolio is the value over $175,700,568, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| KMTSKESTRA MED TECHNOLOGIES LTD | 2,728,679 | $77.2M | 43.94% | 0 | Timeline | ||
| MLYSMINERALYS THERAPEUTICS INC | 1,591,917 | $40M | 22.77% | 0 | Timeline | ||
| AVLNAVALYN PHARMACEUTICALS INC | 929,824 | $26.5M | 15.08% | 0 | Timeline | ||
| AGMBAGOMAB THERAPEUTICS NV | 1,538,702 | $17.1M | 9.72% | 0 | Timeline | ||
| IVAINVENTIVA SA | 3,633,181 | $13.4M | 7.63% | 0 | Timeline | ||
| EVMNEVOMMUNE INC | 97,362 | $804K | 0.46% | -1,294,628 | Timeline | ||
| NYXHNYXOAH S A | 522,057 | $720K | 0.41% | 0 | Timeline |
Sold out in Q3 2026
Positions in the previous quarter's report that this quarter's report no longer lists.
| Security | Shares before | Value before | Type |
|---|---|---|---|
| ABVXABIVAX SA | 78,125 | $10.4M | shares |
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001757283-26-000022 | base | 2026-10-16 |
Filings
Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13G/A 0001757283-26-000025 | IVA | 2026-10-27 | ||
| 13F-HR 0001757283-26-000022 | Quarter ended 2026-09-30 | 2026-10-16 | ||
| 13F-HR 0001757283-26-000015 | Quarter ended 2026-06-30 | 2026-07-22 | acceptance time not in the bulk data set | |
| 13F-HR 0001757283-26-000012 | Quarter ended 2026-03-31 | 2026-05-11 | acceptance time not in the bulk data set | |
| 13F-HR 0001757283-26-000007 | Quarter ended 2025-12-31 | 2026-02-17 | acceptance time not in the bulk data set |